Assistant Professor of Clinical Neurology
UCSF Benioff Children's Hospital
Dr. Sabine Mueller is a pediatric neuro-oncologist who specializes in caring for children with brain tumors and related genetic syndromes. Before completing medical school, she worked as a scientist, director of genomics and project leader for a brain tumor program at AGY Therapeutics, a biotechnology company in South San Francisco.
In her research, Mueller studies treatments for children with brain tumors, looking especially at improving long-term cognitive outcomes.
Mueller earned her medical degree at the Universität Hamburg Faculty of Medicine and earned a doctorate in biochemistry and molecular biology in collaboration with AGY. After a residency in pediatrics at Massachusetts General Hospital, she completed a fellowship in pediatric oncology at UCSF.
Oncolytic virus to potentiate immune-checkpoint blockade in immunologically cold pediatric brain tumors
Our proposal develops an exciting new approach known as oncolytic virus. It is a remarkable fact that some common viruses (e.g. measles, poliovirus) preferentially infect and kill tumor cells. This fact was discovered at the beginning of the 20th century. However, it was not until recently that t
Precision imaging of pediatric high grade gliomas with quantitative diffusion weighted imaging and texture analysis to identify imaging biomarkers that predict tumor genetics and patient outcomes
Pediatric high grade gliomas are molecularly different from adult gliomas and in comparison to adults, children with high grade gliomas have persistently poor clinical outcomes. Molecular markers have been shown to be important for treatment of adult gliomas, and new molecular markers for pediatr
Integrative Analysis of Childhood Cancers
The team, lead by Dr. Vaske is generating mutational, transcriptional, and integrative profiles of individual tumors. Integrative profiles will summarize mutation and expression features at the pathway level, or by other groupings. They also are comparing the profiles of CBTN samples to each othe
PNOC and SJCRH Collaborative DIPG Radiogenomic Investigation
Early analyses by our group and others have suggested that semi-quantitative radiographic (radiomic) features prior to and following therapy may aid disease classification at diagnosis, prognostication, and improve our ability to distinguish between challenging imaging phenotypes following therap
High-grade glioma/astrocytoma (WHO grade III/IV)
High-grade Gliomas (HGG) in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric specific HGG preclinical models. These models are needed to help test the effective
Low-Grade astrocytomas are the most common cancer of the central nervous system in children. They represent a heterogeneous group of tumors that can be discovered anywhere within the brain or spinal cord. Although surgical resection may be curative, up to 20% of children still suffer from the eff
Brainstem glioma- Diffuse intrinsic pontine glioma
A presumptive diagnosis of DIPG based on classic imaging features, in the absence of a histologic diagnosis, has been routinely employed. Increasingly however, histologic confirmation is obtained for both entry into research studies and molecular characterization of the tumor.[
CBTN Annual Investigator Meeting
Precision Medicine Approaches for Children with DIPG
Recent advances in gene expression and sequencing technologies allow oncologists for the first time to use these technologies in real time for clinical decision making and to determine an individualized treatment plan based on each child’s tumor characteristics. Our first feasibility trial used a